Skip to content
Evigrade
CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Antiepileptic, hydantoin derivative (sodium channel blocker)

Updated · Methodology

Mechanism

Phenytoin is a potent inducer of the liver enzymes that metabolise drugs and can lower the levels of drugs that these enzymes clear (phenytoin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The cobicistat SmPC and label class phenytoin as a strong CYP3A inducer, and CYP3A metabolises both cobicistat and the atazanavir or darunavir it boosts (cobicistat SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). The levels of cobicistat and of the boosted drug fall, and human immunodeficiency virus (HIV) treatment may lose its effect, with a risk of drug resistance (cobicistat SmPC, EMA). The documents do not describe any effect of cobicistat on phenytoin. CYP2C9 and CYP2C19 clear phenytoin (phenytoin SmPC, AEMPS), and the cobicistat SmPC does not expect cobicistat to inhibit CYP2C9 or CYP2C19 (cobicistat SmPC, EMA).

Symptoms

The fall in the levels of cobicistat and of the boosted drug causes no symptoms by itself. The main risk is that the antiviral regimen loses its effect and human immunodeficiency virus (HIV) becomes resistant to the drugs (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). Laboratory tests, not how the person feels, show a loss of virologic response (cobicistat FDA label).

Management

The combination is contraindicated. Phenytoin is on the cobicistat contraindication list together with carbamazepine and phenobarbital. As strong CYP3A inducers, they lower the levels of cobicistat and of the drug it boosts, and treatment may lose its effect (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). The same contraindication appears in the SmPCs of the combination tablets of cobicistat with darunavir, atazanavir and elvitegravir (SmPCs of these products, EMA). The phenytoin SmPC does not name cobicistat, but it lists several antiretroviral drugs, including ritonavir, indinavir and lopinavir/ritonavir, among the drugs whose levels and effects phenytoin can change (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For a person taking cobicistat, choose seizure treatment without phenytoin, carbamazepine or phenobarbital (cobicistat SmPC, EMA, and FDA label). No document gives an interval between stopping phenytoin and starting cobicistat. Oxcarbazepine and eslicarbazepine also induce CYP3A but are not contraindicated. With them, consider an alternative anticonvulsant or antiretroviral drug, and if the combination is necessary, monitor for loss of virologic response (cobicistat FDA label). Before starting cobicistat and during treatment, consider possible interactions, review all concomitant medicines and monitor for their adverse effects (cobicistat FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cobicistat

Other interactions with Phenytoin